Learning to distinguish progressive and non-progressive ductal carcinoma in situ

• Published in: Nature reviews. Cancer Vol. 22; no. 12; pp. 663 - 678
• Main Authors: Casasent, Anna K., Almekinders, Mathilde M., Mulder, Charlotta, Bhattacharjee, Proteeti, Collyar, Deborah, Thompson, Alastair M., Jonkers, Jos, Lips, Esther H., van Rheenen, Jacco, Hwang, E. Shelley, Nik-Zainal, Serena, Navin, Nicholas E., Wesseling, Jelle
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.12.2022; Nature Publishing Group
• Subjects: 631/67/1347; 631/67/2322; Biology; Biomedical and Life Sciences; Biomedicine; Biopsy; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer Research; Carcinoma, Intraductal, Noninfiltrating - diagnosis; Carcinoma, Intraductal, Noninfiltrating - genetics; Carcinoma, Intraductal, Noninfiltrating - pathology; Female; Gene expression; Humans; Invasiveness; Mammography; Medical prognosis; Microenvironments; Mutation; Patients; Review Article; Risk groups; Surveillance; Tumor Microenvironment
• ISSN: 1474-175X; 1474-1768
• DOI: 10.1038/s41568-022-00512-y

Ductal carcinoma in situ (DCIS) is a non-invasive breast neoplasia that accounts for 25% of all screen-detected breast cancers diagnosed annually. Neoplastic cells in DCIS are confined to the ductal system of the breast, although they can escape and progress to invasive breast cancer in a subset of patients. A key concern of DCIS is overtreatment, as most patients screened for DCIS and in whom DCIS is diagnosed will not go on to exhibit symptoms or die of breast cancer, even if left untreated. However, differentiating low-risk, indolent DCIS from potentially progressive DCIS remains challenging. In this Review, we summarize our current knowledge of DCIS and explore open questions about the basic biology of DCIS, including those regarding how genomic events in neoplastic cells and the surrounding microenvironment contribute to the progression of DCIS to invasive breast cancer. Further, we discuss what information will be needed to prevent overtreatment of indolent DCIS lesions without compromising adequate treatment for high-risk patients. ‘Ductal carcinoma in situ’ (DCIS) describes abnormal cells in the milk ducts. DCIS is often non-invasive, although a small proportion of cases leave the ducts and progress to invasive breast cancer. This Review discusses the existing data for distinguishing progressive and non-progressive DCIS, with a focus on informing current disease management strategies.